The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Open accessAbstract
Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder. It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages. In the general population, its incidence is approximately 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews. The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells. Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also associated with neurological impairment, either severe in type 2 or variable in type 3. A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes. Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases. Patients with type-1 GD—but also carriers of GBA1 mutation—have been found to be predisposed to developing Parkinson’s disease, and the risk of neoplasia associated with the disease is still subject to discussion. Disease-specific treatment consists of intravenous enzyme replacement therapy (ERT) using one of the currently available molecules (imiglucerase, velaglucerase, or taliglucerase). Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105233242104 · Cited by 1,252
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896 · cited 1×
“Chitotriosidase is produced in large quantities by Gaucher cells, and it has been used as a biomarker since 1994 [135].”
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Phenotype, diagnosis, and treatment of Gaucher's disease
Grabowski, G. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61522-6 · Cited by 634
Pastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
The Gaucher Registry: Demographics and Disease Characteristics of 1698 Patients With Gaucher Disease
Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, P., Pastores, G., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., Weinreb, N. J., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2835 · Cited by 574
LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase
Reczek, D., Schwake, M., Schröder, J., Hughes, H., Blanz, J., Jin, X., Brondyk, W., Van Patten, S., Edmunds, T., & Saftig, P. (2007) · Cell · doi:10.1016/j.cell.2007.10.018 · Cited by 542
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475 · cited 1×
“(A) Normally, GCase interacts with its substrate glucosylceramide (GlcCer) as well as monomers of α-synuclein in lysosomes, facilitating the breakdown of both at acidic pH; (B) Mutated GCase or decreased levels of GCase result in a slowdown of α-synuclein degradation and a gradual build up of GlcCer, with the formatio…”
BackgroundThe human glucocerebrosidase gene and pseudogene: Structure and evolution
Horowitz, M., Wilder, S., Horowitz, Z., Reiner, O., Gelbart, T., & Beutler, E. (1989) · Genomics · doi:10.1016/0888-7543(89)90319-4 · Cited by 428
Therapeutic goals in the treatment of Gaucher disease
Pastores, G. M., Weinreb, N. J., Aerts, H., Andria, G., Cox, T. M., Giralt, M., Grabowski, G. A., Mistry, P. K., & Tylki-Szymańska, A. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.009 · Cited by 422
Survival and dementia in GBA ‐associated Parkinson's disease: The mutation matters
Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., Zecchinelli, A. L., Canesi, M., Mariani, C. B., Meucci, N., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24777 · Cited by 406
Gaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399
Kristinsson, S. Y., Gridley, G., Hoover, R. N., Check, D., & Landgren, O. (2014) · Haematologica · doi:10.3324/haematol.2013.092460 · Cited by 345
Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease
Koprivica, V., Stone, D. L., Park, J. K., Callahan, M., Frisch, A., Cohen, I. J., Tayebi, N., & Sidransky, E. (2000) · The American Journal of Human Genetics · doi:10.1086/302925 · Cited by 334
Boot, R. G., Verhoek, M., de Fost, M., Hollak, C. E. M., Maas, M., Bleijlevens, B., van Breemen, M. J., van Meurs, M., Boven, L. A., Laman, J. D., et al. (2004) · Blood · doi:10.1182/blood-2003-05-1612 · Cited by 334
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease
Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012393 · Cited by 332
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
Ron, I., & Horowitz, M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi240 · Cited by 330
McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Dekker, N., van Dussen, L., Hollak, C. E. M., Overkleeft, H., Scheij, S., Ghauharali, K., van Breemen, M. J., Ferraz, M. J., Groener, J. E. M., Maas, M., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352971 · Cited by 292
Boven, L. A., van Meurs, M., Boot, R. G., Mehta, A. B., Boon, L., Aerts, J. M. F. G., & Laman, J. D. (2004) · American Journal of Clinical Pathology · doi:10.1309/bg5v-a8jr-dqh1-m7hn · Cited by 290
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Parenti, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900036 · Cited by 273
Skeletal aspects of Gaucher disease: a review
Wenstrup, R. J., Roca-Espiau, M., Weinreb, N. J., & Bembi, B. (2002) · The British Journal of Radiology · doi:10.1259/bjr.75.suppl_1.750002 · Cited by 273
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 263
Berkovic, S. F., Dibbens, L. M., Oshlack, A., Silver, J. D., Katerelos, M., Vears, D. F., Lüllmann-Rauch, R., Blanz, J., Zhang, K. W., Stankovich, J., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.12.019 · Cited by 260
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000276989.17578.02 · Cited by 252
Mistry, P. K., Liu, J., Yang, M., Nottoli, T., McGrath, J., Jain, D., Zhang, K., Keutzer, J., Chuang, W.-L., Mehal, W. Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003308107 · Cited by 245
Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N., & Cox, T. M. (1997) · QJM · doi:10.1093/qjmed/90.1.19 · Cited by 245
Gaucher disease and cancer incidence: a study from the Gaucher Registry
Rosenbloom, B. E., Weinreb, N. J., Zimran, A., Kacena, K. A., Charrow, J., & Ward, E. (2005) · Blood · doi:10.1182/blood-2004-12-4672 · Cited by 235
The risk of Parkinson's disease in type 1 Gaucher disease
Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9055-0 · Cited by 223
Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
Alcalay, R. N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W. K., Pauciulo, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.313 · Cited by 217
Clonal immunoglobulin against lysolipids in the origin of myeloma
Nair, S., Branagan, A. R., Liu, J., Boddupalli, C. S., Mistry, P. K., & Dhodapkar, M. V. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508808 · Cited by 203
Kaplan, P., Andersson, H. C., Kacena, K. A., & Yee, J. D. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.6.603 · Cited by 198
Rolfs, A., Giese, A.-K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., Böttcher, T., Lukas, J., Hübner, R., Gölnitz, U., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079732 · Cited by 197
Orvisky, E., Park, J. K., LaMarca, M. E., Ginns, E. I., Martin, B. M., Tayebi, N., & Sidransky, E. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00117-8 · Cited by 193
Glucosylsphingosine is a key biomarker of Gaucher disease
Murugesan, V., Chuang, W., Liu, J., Lischuk, A., Kacena, K., Lin, H., Pastores, G. M., Yang, R., Keutzer, J., Zhang, K., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24491 · Cited by 191
Identification of human CCR8 as a CCL18 receptor
Islam, S. A., Ling, M. F., Leung, J., Shreffler, W. G., & Luster, A. D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130240 · Cited by 190
Increased incidence of cancer in adult Gaucher disease in Western Europe
de Fost, M., vom Dahl, S., Weverling, G. J., Brill, N., Brett, S., Häussinger, D., & Hollak, C. E. M. (2006) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2005.08.004 · Cited by 184
Mistry, P. K., Sirrs, S., Chan, A., Pritzker, M. R., Duffy, T. P., Grace, M. E., Meeker, D. P., & Goldman, M. E. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00122-1 · Cited by 175
Dunbar, C. E., Kohn, D. B., Schiffmann, R., Barton, N. W., Nolta, J. A., Esplin, J. A., Pensiero, M., Long, Z., Lockey, C., Emmons, R. V. B., et al. (1998) · Human Gene Therapy · doi:10.1089/10430349850019463 · Cited by 174
Yap, T. L., Gruschus, J. M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., & Lee, J. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237859 · Cited by 174
Cytokines in Gaucher's disease.
Barak, V., Acker, M., Nisman, B., et al. (1999) · PubMed · Cited by 172
Progranulin in neurodegenerative disease
Petkau, T. L., & Leavitt, B. R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.04.003 · Cited by 169
Taddei, T. H., Kacena, K. A., Yang, M., Yang, R., Malhotra, A., Boxer, M., Aleck, K. A., Rennert, G., Pastores, G. M., & Mistry, P. K. (2009) · American Journal of Hematology · doi:10.1002/ajh.21362 · Cited by 164
Substrate reduction therapy of glycosphingolipid storage disorders
Aerts, J., Hollak, C., Boot, R., Groener, J., & Maas, M. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0272-5 · Cited by 163
Kinghorn, K. J., Grönke, S., Castillo-Quan, J. I., Woodling, N. S., Li, L., Sirka, E., Gegg, M. E., Mills, K. A., Hardy, J., Bjedov, I., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4527-15.2016 · Cited by 163
Type 2 Gaucher disease: 15 new cases and review of the literature
Mignot, C., Doummar, D., Maire, I., & de Villemeur, T. B. (2005) · Brain and Development · doi:10.1016/j.braindev.2005.04.005 · Cited by 161
Cox, T. M., Drelichman, G., Cravo, R., Balwani, M., Burrow, T. A., Martins, A. M., Lukina, E., Rosenbloom, B., Ross, L., Angell, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61841-9 · Cited by 160
Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages
Aflaki, E., Moaven, N., Borger, D. K., Lopez, G., Westbroek, W., Chae, J. J., Marugan, J., Patnaik, S., Maniwang, E., Gonzalez, A. N., et al. (2016) · Aging Cell · doi:10.1111/acel.12409 · Cited by 158
Sanchez-Martinez, A., Beavan, M., Gegg, M. E., Chau, K.-Y., Whitworth, A. J., & Schapira, A. H. V. (2016) · Scientific Reports · doi:10.1038/srep31380 · Cited by 158
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1
Mistry, P. K., Lukina, E., Turkia, H. B., Amato, D., Baris, H. N., Dasouki, M., Ghosn, M. G., Mehta, A. B., Packman, S., Pastores, G. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.459 · Cited by 156
Lukina, E., Watman, N. P., Arreguin, E. Á., Banikazemi, M., Dragosky, M. O., Iastrebner, M., Rosenbaum, H., Phillips, M., Pastores, G. M., Rosenthal, D. I., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273151 · Cited by 155
Stirnemann, J., Vigan, M., Hamroun, D., Heraoui, D., Rossi‐Semerano, L., Berger, M. G., Rosé, C., Camou, F., Serratrice, J., Grosbois, B., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-77 · Cited by 154
Self-citationTEN YEARS' EXPERIENCE OF BONE MARROW TRANSPLANTATION FOR GAUCHER DISEASE
Ringdén, O. T. H., Groth, C. G., Erikson, A., Granqvist, S., Månsson, J., & Sparrelid, E. (1995) · Transplantation · doi:10.1097/00007890-199503000-00011 · Cited by 153
Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher Disease
WENSTRUP, R. J., Kacena, K. A., Kaplan, P. B., Pastores, G. M., Prakash‐Cheng, A., Zimran, A., & Hangartner, T. N. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061004 · Cited by 151
Glucocerebrosidase is shaking up the synucleinopathies
Siebert, M., Sidransky, E., & Westbroek, W. (2014) · Brain · doi:10.1093/brain/awu002 · Cited by 150
The role of saposin C in Gaucher disease
Tamargo, R. J., Velayati, A., Goldin, E., & Sidransky, E. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.04.024 · Cited by 148
The clinical management of type 2 Gaucher disease
Weiss, K., Gonzalez, A. N., Lopez, G. J., Pedoeim, L., Groden, C. A., & Sidransky, E. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.008 · Cited by 148
Elevated Levels of M-CSF, sCD14 and IL8 in Type 1 Gaucher Disease
Hollak, C. E. M., Evers, L. M., Aerts, J. M. F. G., & van Oers, M. H. J. (1997) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.1997.0137 · Cited by 147
Grabowski, G. A., Zimran, A., & Ida, H. (2015) · American Journal of Hematology · doi:10.1002/ajh.24063 · Cited by 146
Tylki‐Szymańska, A., Vellodi, A., El-Beshlawy, A. M., et al. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-9009-6 · Cited by 144
Cox, T. M., Aerts, J. M. F. G., Belmatoug, N., Cappellini, M. D., Dahl, S. V., Goldblatt, J., Grabowski, G. A., Hollak, C. E. M., Hwu, W., Maas, M. M., et al. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0779-z · Cited by 137
Self-citationMistry, P. K., Weinreb, N. J., Kaplan, P. B., Cole, J. A., Gwosdow, A. R., & Hangartner, T. N. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.10.011 · Cited by 132
Malignancies and monoclonal gammopathy in G aucher disease; a systematic review of the literature
Arends, M. L., van Dussen, L., Biegstraaten, M., & Hollak, C. E. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12335 · Cited by 131
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
Deegan, P. B., Moran, M. T., McFarlane, I., Schofield, J. P., Boot, R. G., Aerts, J. M. F. G., & Cox, T. M. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.05.005 · Cited by 130
Individualization of long-term enzyme replacement therapy for Gaucher disease
Andersson, H. C., Charrow, J., Kaplan, P. B., Mistry, P. K., Pastores, G. M., Prakash‐Cheng, A., Rosenbloom, B. E., Scott, C. R., Wappner, R. S., & Weinreb, N. J. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000153660.88672.3c · Cited by 128
van Breemen, M. V., de Fost, M., Voerman, J., Laman, J., Boot, R., Maas, M., Hollak, C., Aerts, J., & Rezaee, F. (2007) · Biochimica et Biophysica Acta · doi:10.1016/j.bbadis.2007.04.002 · Cited by 128
Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy
Deegan, P., Pavlova, E., Tindall, J., Stein, P., Bearcroft, P., Mehta, A., Hughes, D., Wraith, J. E., & Cox, T. M. (2011) · Medicine · doi:10.1097/md.0b013e3182057be4 · Cited by 126
Analysis of the glucocerebrosidase gene in Parkinson's disease
Sato, C., Morgan, A. R., Lang, A. E., Salehi‐Rad, S., Kawarai, T., Meng, Y., Ray, P. N., Farrer, L. A., George‐Hyslop, P. S., & Rogaeva, E. A. (2004) · Movement Disorders · doi:10.1002/mds.20319 · Cited by 125
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
Aerts, J. M. F. G., Kallemeijn, W. W., Wegdam, W., Ferraz, M. J., van Breemen, M. J., Dekker, N., Kramer, G., Poorthuis, B. J. H. M., Groener, J. E. M., Cox‐Brinkman, J., et al. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9308-6 · Cited by 124
Bone density in type 1 gaucher disease
Pastores, G. M., Wallenstein, S. R., Desnick, R. J., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111125 · Cited by 123
Gaucher disease: insights from a rare Mendelian disorder.
Sidransky, E. (2012) · PubMed · Cited by 121
Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity
Yap, T. L., Velayati, A., Sidransky, E., & Lee, J. C. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.11.010 · Cited by 119
Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease
Mistry, P. K., Liu, J., Sun, L., Chuang, W., Yuen, T., Yang, R., Lü, P., Zhang, K., Li, J., Keutzer, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400768111 · Cited by 117
Human Chitotriosidase: a Sensitive Biomarker of Sarcoidosis
Bargagli, E., Bennett, D., Maggiorelli, C., Sipio, P. D., Margollicci, M. A., Bianchi, N., & Rottoli, P. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9754-4 · Cited by 113
Vaccaro, A. M., Motta, M., Tatti, M., Scarpa, S., Masuelli, L., Bhat, M., Vanier, M. T., Tylki‐Szymańska, A., & Salvioli, R. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq204 · Cited by 113
Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
Jian, J., Tian, Q., Hettinghouse, A., Zhao, S., Liu, H., Wei, J., Grünig, G., Zhang, W., Setchell, K. D. R., Sun, Y., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.010 · Cited by 113
Lysosomal integral membrane protein-2: A new player in lysosome-related pathology
Gonzalez, A. N., Valeiras, M., Sidransky, E., & Tayebi, N. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.005 · Cited by 111
An overview on bone manifestations in Gaucher disease
Mikosch, P., & Hughes, D. A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0841-y · Cited by 110
Weinreb, N. J., Barranger, J. A., Packman, S., Prakash‐Cheng, A., Rosenbloom, B. E., Sims, K. B., Angell, J. E., Skrinar, A. M., & Pastores, G. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00811.x · Cited by 107
de Fost, M., Out, T., Wilde, F. D., Tjin, E., Pals, S., van Oers, M. V., Boot, R., Aerts, J., Maas, M., Dahl, S., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0441-8 · Cited by 107
Campeau, P. M., Rafei, M., Boivin, M., Sun, Y., Grabowski, G. A., & Galipeau, J. (2009) · Blood · doi:10.1182/blood-2009-02-205708 · Cited by 100
Ron, I., Rapaport, D., & Horowitz, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq292 · Cited by 99
Belmatoug, N., Rocco, M. D., Fraga, C., Giraldo, P., Hughes, D. A., Lukina, E., Maison‐Blanche, P., Merkel, M., Niederau, C., Plöckinger, U., et al. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.07.011 · Cited by 98
Self-citationThe fine structure of the cerebroside occurring in Gaucher's disease.
Lee, R. E. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.61.2.484 · Cited by 95
Association Between Progranulin and Gaucher Disease
Jian, J., Zhao, S., Tian, Q., Liu, H., Zhao, Y., Chen, W., Grünig, G., Torres, P., Wang, B. C., Zeng, B. J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.004 · Cited by 95
Pulmonary pathology in Gaucher's disease
Amir, G., & Ron, N. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90092-8 · Cited by 91
Transglycosidase Activity of Chitotriosidase
Aguilera, B., der Vlugt, K. G.-V., Helmond, M. T. J., Out, J. M. M., Donker-Koopman, W., Groener, J., Boot, R., Renkema, G., van der Marel, G. A., van Boom, J. H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301804200 · Cited by 90
Hughes, D. A., Cappellini, M. D., Berger, M. G., Droogenbroeck, J. V., de Fost, M., Janić, D., Marinakis, T., Rosenbaum, H., Villarubia, J., Zhukovskaya, E. V., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06701.x · Cited by 89
Self-citationDamiano, A. M., Pastores, G. M., & Ware, J. E. (1998) · Quality of Life Research · doi:10.1023/a:1008814105603 · Cited by 87
The pathogenesis of glycosphingolipid storage disorders
Ginzburg, L., Kacher, Y., & Futerman, A. H. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.03.003 · Cited by 87
Hyperferritinemia and iron overload in type 1 Gaucher disease
Stein, P., Yu, H. J., Jain, D., & Mistry, P. K. (2010) · American Journal of Hematology · doi:10.1002/ajh.21721 · Cited by 87
Dahl, S. V., Poll, L. W., Rocco, M. D., Ciana, G., Denes, C. L., Mariani, G., & Maas, M. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104623 · Cited by 86
Lukina, E., Watman, N. P., Dragosky, M. O., Pastores, G. M., Arreguin, E. Á., Rosenbaum, H., Zimran, A., Angell, J. E., Ross, L. H., Puga, A. C., et al. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.04.002 · Cited by 85
Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study
Biegstraaten, M., Mengel, E., Maródi, L., Petakov, M. S., Niederau, C., Giraldo, P., Hughes, D. A., Mršić, M., Mehta, A. B., Hollak, C. E. M., et al. (2010) · Brain · doi:10.1093/brain/awq198 · Cited by 85
Effect of enzyme replacement therapy on gammopathies in Gaucher disease
Brautbar, A., Elstein, D., Pines, G., Abrahamov, A., & Zimran, A. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2003.10.007 · Cited by 83
Clinical and genetic study of Japanese patients with type 3 Gaucher disease
Tajima, A., Yokoi, T., Ariga, M., Ito, T., Kaneshiro, E., Eto, Y., & Ida, H. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.05.001 · Cited by 83
Hollak, C. E. M., Maas, M. M., Akkerman, E. M., den Heeten, A., & Aerts, J. M. F. G. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2001.0474 · Cited by 83
Pavlova, E., Archer, J., Wang, S. Z., Dekker, N., Aerts, J. M. F. G., Karlsson, S., & Cox, T. M. (2014) · The Journal of Pathology · doi:10.1002/path.4452 · Cited by 81
A mutation in SCARB2 is a modifier in gaucher disease
Velayati, A., DePaolo, J., Gupta, N., Choi, J. H., Moaven, N., Westbroek, W., Göker-Alpan, Ö., Goldin, E., Stubblefield, B. K., Kolodny, E. H., et al. (2011) · Human Mutation · doi:10.1002/humu.21566 · Cited by 81
Gastrointestinal disturbances and their management in miglustat‐treated patients
Belmatoug, N., Burlina, A., Giraldo, P., Hendriksz, C. J., Kuter, D. J., Mengel, E., & Pastores, G. M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9368-7 · Cited by 80
Self-citationvan Dussen, L., Hendriks, E. J., Groener, J. E. M., Boot, R. G., Hollak, C. E. M., & Aerts, J. M. F. G. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9711-x · Cited by 78
Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype–genotype correlation
Aharon‐Peretz, J., Badarny, S., Rosenbaum, H., & Gershoni‐Baruch, R. (2005) · Neurology · doi:10.1212/01.wnl.0000176987.47875.28 · Cited by 76
The Erlenmeyer flask bone deformity in the skeletal dysplasias
Faden, M., Krakow, D., Ezgü, F. S., et al. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32253 · Cited by 75
Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
Bonella, F., & Costabel, U. (2014) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1371527 · Cited by 74
Lesage, S., Patin, É., Condroyer, C., Leutenegger, A., Lohmann, E., Giladi, N., Bar‐Shira, A., Belarbi, S., Hecham, N., Pollak, P., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq081 · Cited by 72
Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice
Dahl, M., Doyle, A., Olsson, K., Månsson, J., Marques, A. R. A., Mirzaian, M., Aerts, J. M. F. G., Ehinger, M., Rothe, M., Modlich, U., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.16 · Cited by 70
A monozygotic twin pair with highly discordant Gaucher phenotypes
Biegstraaten, M., van Schaik, I. N., Aerts, J. M. F. G., Langeveld, M., Mannens, M. M. A. M., Bour, L. J., Sidransky, E., Tayebi, N., Fitzgibbon, E. J., & Hollak, C. E. M. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.10.007 · Cited by 70
Quality of life assessment in adults with type 1 Gaucher disease
Masek, B. J., Sims, K. B., Bove, C. M., Korson, M. S., Short, P., & Norman, D. K. (1999) · Quality of Life Research · doi:10.1023/a:1008859420641 · Cited by 69
Langeveld, M., de Fost, M., Aerts, J., Sauerwein, H., & Hollak, C. (2008) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2007.09.002 · Cited by 68
Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies
Barkhuizen, M., Anderson, D. G., & Grobler, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.004 · Cited by 68
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
Kamath, R. S., Lukina, E., Watman, N. P., Dragosky, M. O., Pastores, G. M., Arreguin, E. Á., Rosenbaum, H., Zimran, A., Aguzzi, R., Puga, A. C., et al. (2014) · Skeletal Radiology · doi:10.1007/s00256-014-1891-9 · Cited by 66
Therapeutic approaches to bone pathology in Gaucher disease: past, present and future.
Goker-Alpan, O. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.08.004 · Cited by 65
Taddei, T. H., Dziura, J. D., Chen, S., Yang, R., Hyogo, H., Sullards, C., Cohen, D. E., Pastores, G. M., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9070-1 · Cited by 64
George, R., McMahon, J., Lytle, B. W., Clark, B., & Lichtin, A. E. (2001) · Clinical Genetics · doi:10.1034/j.1399-0004.2001.590511.x · Cited by 63
Mirzaian, M., Wisse, P., Ferraz, M. J., Gold, H., Donker-Koopman, W., Verhoek, M., Overkleeft, H., Boot, R., Kramer, G., Dekker, N., et al. (2015) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2015.01.006 · Cited by 63
Glucosylceramidases and malignancies in mammals
Astudillo, L. M., Therville, N., Colacios, C., Ségui, B., Andrieu‐Abadie, N., & Levade, T. (2015) · Biochimie · doi:10.1016/j.biochi.2015.11.009 · Cited by 53
Self-citationLong‐term treatment outcomes in G aucher disease
Charrow, J., & Scott, C. R. (2015) · American Journal of Hematology · doi:10.1002/ajh.24056 · Cited by 50
Yap, T. L., Jiang, Z., Heinrich, F., Gruschus, J. M., Pfefferkorn, C. M., Barros, M., Curtis, J. E., Sidransky, E., & Lee, J. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610584 · Cited by 49
B cell lymphoma and myeloma in murine Gaucher's disease
Pavlova, E., Wang, S., Archer, J., Dekker, N., Aerts, J. M. F. G., Karlsson, S., & Cox, T. (2013) · The Journal of Pathology · doi:10.1002/path.4227 · Cited by 48
Schroen, B. L. M., Leenders, J. J., van Erk, A., Bertrand, A., van Loon, M., van Leeuwen, R. E. W., Kubben, N., Duisters, R. F. J. J., Schellings, M. W. M., Janssen, B. J., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070145 · Cited by 48
Saposin C Protects Glucocerebrosidase against α-Synuclein Inhibition
Yap, T. L., Gruschus, J. M., Velayati, A., Sidransky, E., & Lee, J. C. (2013) · Biochemistry · doi:10.1021/bi401191v · Cited by 47
Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease
Landgren, O., Turesson, I., Gridley, G., & Caporaso, N. E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.11.1189 · Cited by 46
Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment
MEKINIAN, A., Stirnemann, J., Belmatoug, N., Heraoui, D., Fantin, B., Fain, O., Charpentier, A., & Rosé, C. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.04.002 · Cited by 45
Self-citationCutaneous manifestations of Gaucher disease
Goldblatt, J., & Beighton, P. (1984) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1984.tb04731.x · Cited by 44
Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleeding
Spectre, G., Roth, B., Ronen, G., Rosengarten, D., Elstein, D., Zimran, A., Varon, D., & Revel‐Vilk, S. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08613.x · Cited by 41
de Fost, M., Langeveld, M., Franssen, R., Hutten, B. A., Groener, J. E. M., de Groot, E., Mannens, M. M. A. M., Bikker, H., Aerts, J. M. F. G., Kastelein, J. J. P., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.027 · Cited by 41
Hollak, C. E. M., Belmatoug, N., Cole, J. A., Dahl, S. V., Deegan, P. B., Goldblatt, J., Rosenbloom, B. E., van Dussen, L., Tylki‐Szymańska, A., Weinreb, N. J., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09175.x · Cited by 40
Self-citationStein, P., Malhotra, A., Haims, A. H., Pastores, G. M., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9175-6 · Cited by 40
Role of CCL 18 in asthma and lung immunity
Tsicopoulos, A., Chang, Y., Yahia, S. A., de Nadaı̈, P., & Chenivesse, C. (2012) · Clinical & Experimental Allergy · doi:10.1111/cea.12065 · Cited by 40
Bussink, A. P., Verhoek, M., Vreede, J., der Vlugt, K. G., Donker‐Koopman, W. E., Sprenger, R. R., Hollak, C. E. M., Aerts, J. M. F. G., & Boot, R. G. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07259.x · Cited by 38
Lecourt, S., Vanneaux, V., Cras, A., Freida, D., Heraoui, D., Herbi, L., Caillaud, C., Chomienne, C., Marolleau, J., Belmatoug, N., et al. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0365 · Cited by 35
Self-citationNew Directions in Gaucher Disease
Horowitz, M., Elstein, D., Zimran, A., & Göker-Alpan, Ö. (2016) · Human Mutation · doi:10.1002/humu.23056 · Cited by 35
Mucci, J. M., Cuello, M. F., Kisinovsky, I., Larroudé, M. S., Delpino, M. V., & Rozenfeld, P. A. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.05.009 · Cited by 31
Gaucher Disease with Communicating Hydrocephalus and Cardiac Involvement
Cındık, N., Özçay, F., Süren, D., Akkoyun, İ., Gökdemir, M., Varan, B., Alehan, F., Özbek, N. Y., & Tokel, K. (2009) · Clinical Cardiology · doi:10.1002/clc.20348 · Cited by 31
Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C
Gruschus, J. M., Jiang, Z., Yap, T. L., Hill, S. A., Grishaev, A., Piszczek, G., Sidransky, E., & Lee, J. C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.024 · Cited by 30
Fuller, M., Szer, J., Stark, S., & Fletcher, J. M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.07.026 · Cited by 29
Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt
Abdelwahab, M. S., Blankenship, D., & Schiffmann, R. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000055 · Cited by 27
Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy
Grosbois, B., Rosé, C., Noël, E., Serratrice, J., Dobbelaere, D., Gressin, V., Cherin, P., Hartmann, A., Javier, R., Clerson, P., et al. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.04.002 · Cited by 26
Self-citationYang, C., Wang, H., Zhu, D., Hong, C. S., Dmitriev, P., Zhang, C., Li, Y., Ikejiri, B. L., Brady, R. O., & Zhuang, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424288112 · Cited by 25
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease
Medrano-Engay, B., Irún, P., Gervas‐Arruga, J., Andrade‐Campos, M., Andreu, V., Alfonso, P., Pocovı́, M., & Giraldo, P. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.07.007 · Cited by 25
Sellos-Moura, M., Barzegar, S., Pan, L., Shi, P., Oommen, S., Durant, J., & Ruiz, J. A. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.020 · Cited by 22
Vigan, M., Stirnemann, J., Caillaud, C., Froissart, R., Boutten, A., Fantin, B., Belmatoug, N., & Mentré, F. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-95 · Cited by 21
Self-citationImpact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease
Stirnemann, J., Boutten, A., Vincent, C., MEKINIAN, A., Heraoui, D., Fantin, B., Fain, O., Mentré, F., & Belmatoug, N. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.10.014 · Cited by 20
Self-citationA case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency
Hřebíček, M., Hodaňová, K., Ledvinová, J., Sokolová, J., Elleder, M., Zeman, J., Vepřeková, L., Musilová, J., Aerts, J. M. F. G., Renkema, G. H., et al. (1996) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00198347 · Cited by 17
Berger, J., Stirnemann, J., Bourgne, C., Pereira, B., Pigeon, P., Heraoui, D., Froissart, R., Rapatel, C., Rosé, C., Belmatoug, N., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08989.x · Cited by 14
Self-citation
Cited by
Lysosomal Biology and Function: Modern View of Cellular Debris Bin
Trivedi, P. C., Bartlett, J. J., & Pulinilkunnil, T. (2020) · Cells · doi:10.3390/cells9051131 · Cited by 296
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
Dardis, A., Michelakakis, H., Rozenfeld, P., Fumic, K., Wagner, J., Pavan, E., Fuller, M., Revel-Vilk, S., Hughes, D., Cox, T., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02573-6 · Cited by 61
Metadata
- Authors
- Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., Billette de Villemeur, T., & Berger, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-02-17
- Volume
- 18
- Issue
- 2
- Pages
- 441
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2588291989
- Cited by
- 868
- References
- 151
- FWCI
- 36.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.